Display options
Cite
Yeganeh B, Hashemi M, de Serres FJ, et al. Different faces of hepatocellular carcinoma as a health threat in 21st century. Hepat Mon. 2013;13(2):e9308doi: 10.5812/hepatmon.9308.
Yeganeh, B., Hashemi, M., de Serres, F. J., Los, M. J., & Ghavami, S. (2013). Different faces of hepatocellular carcinoma as a health threat in 21st century. Hepatitis monthly, 13(2), e9308. https://doi.org/10.5812/hepatmon.9308
Yeganeh, Behzad, et al. "Different faces of hepatocellular carcinoma as a health threat in 21st century." Hepatitis monthly vol. 13,2 (2013): e9308. doi: https://doi.org/10.5812/hepatmon.9308
Yeganeh B, Hashemi M, de Serres FJ, Los MJ, Ghavami S. Different faces of hepatocellular carcinoma as a health threat in 21st century. Hepat Mon. 2013 Feb 04;13(2):e9308. doi: 10.5812/hepatmon.9308. Print 2013 Feb. PMID: 23613688; PMCID: PMC3632001.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2013 Feb 04;13(2):e9308. doi: 10.5812/hepatmon.9308. Print 2013 Feb.

Different faces of hepatocellular carcinoma as a health threat in 21st century.

Hepatitis monthly

Behzad Yeganeh, Mohammad Hashemi, Fredrick J de Serres, Marek J Los, Saeid Ghavami

Affiliations

  1. Department of Physiology, University of Manitoba, Winnipeg, Canada.

PMID: 23613688 PMCID: PMC3632001 DOI: 10.5812/hepatmon.9308

[No abstract available.]

Keywords: Aflatoxins; Alpha 1 Antitrypsin; Biological Markers; Hepatitis B Virus; Hepatitis C; lobaplatin

References

  1. AIDS. 2005 Mar 24;19(6):593-601 - PubMed
  2. Hepatol Res. 2005 Dec;33(4):292-7 - PubMed
  3. J Gastroenterol Hepatol. 2010 Sep;25(9):1485-92 - PubMed
  4. Hepat Mon. 2012 Oct;12(10 HCC):e7635 - PubMed
  5. Biomed Pharmacother. 2011 Jun;65(3):137-41 - PubMed
  6. J Hepatol. 2008;48 Suppl 1:S20-37 - PubMed
  7. Hepat Mon. 2012 Oct;12(10 HCC):e7434 - PubMed
  8. Hepat Mon. 2012 Oct;12(10 HCC):e6031 - PubMed
  9. Ann Oncol. 1997 Jul;8(7):695-6 - PubMed
  10. Anticancer Drugs. 1993 Feb;4(1):51-5 - PubMed
  11. Am J Gastroenterol. 2000 May;95(5):1316-22 - PubMed
  12. Oncogene. 2007 Apr 2;26(15):2166-76 - PubMed
  13. Gut. 2012 May;61 Suppl 1:i47-58 - PubMed
  14. Hepat Mon. 2012 Oct;12(10 HCC):e7240 - PubMed
  15. Clin Genet. 2003 Jun;63(6):490-509 - PubMed
  16. Hepat Mon. 2012 Oct;12(10 HCC):e6894 - PubMed
  17. Can J Physiol Pharmacol. 2009 Oct;87(10):743-55 - PubMed
  18. Hepat Mon. 2012 Oct;12(10 HCC):e7042 - PubMed
  19. J Immunol. 2008 Oct 1;181(7):4666-75 - PubMed
  20. J Hepatol. 2006;44(1 Suppl):S6-9 - PubMed
  21. Hepat Mon. 2012 Oct;12(10 HCC):e5943 - PubMed
  22. Expert Opin Investig Drugs. 2001 Jan;10(1):119-28 - PubMed
  23. Diabetes Res Clin Pract. 2007 Feb;75(2):246-8 - PubMed
  24. Hepat Mon. 2012 Oct;12(10 HCC):e7238 - PubMed
  25. Cell Res. 2010 Mar;20(3):314-31 - PubMed
  26. Eur J Pharmacol. 2009 Dec 25;625(1-3):73-83 - PubMed
  27. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  28. Liver Int. 2007 Mar;27(2):155-62 - PubMed
  29. Hepat Mon. 2012 Oct;12(10 HCC):e7492 - PubMed
  30. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:115-22 - PubMed
  31. J Korean Med Sci. 2010 Dec;25(Suppl):S36-40 - PubMed
  32. J Gastroenterol Hepatol. 2011 Jun;26(6):960-4 - PubMed
  33. Hepat Mon. 2011 Mar;11(3):155-6 - PubMed
  34. Hepat Mon. 2012 Oct;12(10 HCC):e7876 - PubMed
  35. Clin Genet. 2003 Nov;64(5):382-97 - PubMed
  36. Langenbecks Arch Surg. 2012 Jun;397(5):681-95 - PubMed
  37. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  38. Biochim Biophys Acta. 2008 Feb;1783(2):297-311 - PubMed
  39. Hepat Mon. 2012 Oct;12(10 HCC):e5871 - PubMed
  40. Best Pract Res Clin Gastroenterol. 2006;20(6):1075-83 - PubMed
  41. Semin Liver Dis. 2010 Feb;30(1):3-16 - PubMed
  42. Hepat Mon. 2012 Oct;12(10 HCC):e6122 - PubMed
  43. Cancer Chemother Pharmacol. 1993;33(1):43-7 - PubMed
  44. Biomed Pharmacother. 2012 Apr;66(3):161-6 - PubMed
  45. Cleve Clin J Med. 2002 Dec;69(12):928-9, 933, 936 passim - PubMed
  46. Cancer Res. 1967 Dec;27(12):2370-6 - PubMed

Publication Types